TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05625594
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04058210
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet for oral administration.
Study: NCT05229510
Drug: 50 mg/mL Virazole Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
Study: NCT05229510
Drug: 100 mg/mL Virazole Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
Study: NCT05229510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 or 20 ml total volume) aerosolized and administered until solution depleted
Study: NCT05785234
Drug: sufentanil-remimazolam group
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 0.5 ng·ml-1 of sufentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 0.2 - 0.6 ng·ml-1 of sufentanil.
Study: NCT05785234
Drug: remifentanil-remimazolam group
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 4 ng·ml-1 of remifentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 2-6 ng·ml-1 of remifentanil.
Study: NCT06157450
Drug: ZSP1273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive ZSP1273 orally.
Study: NCT05985759
Drug: N acetyle cystiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: N acetyle cystien is administerd due to its antibacterial action and anti inflamatory action
Study: NCT04371653
Drug: PRIM-DJ2727
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration orally
Study: NCT04371653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration orally placebo
Study: NCT05472948
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)
Study: NCT06164509
Drug: Alphintern® , tablet, Amoun, Egypt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.
Study: NCT06494527
Drug: RG002C0106
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG002C0106 is a siRNA drug targeting complement C3 to silence the related gene through the RNA interfering mechanism and inhibit the expression of C3 protein.
Study: NCT05882032
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05232123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral product formulated in MCT (medium chain triglyceride) oil
Study: NCT05169021
Drug: Amlodipine folic acid 5.8mg+intensive antihypertensive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure(SBP\<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.
Study: NCT05169021
Drug: Amlodipine folic acid 5.8mg+standard antihypertensive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.
Study: NCT04772443
Drug: DWJ1506
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWJ1506
Study: NCT04772443
Drug: DWJ1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWJ1507
Study: NCT04772443
Drug: DWC202011
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202011
Study: NCT04772443
Drug: DWJ1177
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202011
Study: NCT05764317
Drug: Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg
Normalized name: amlodipine / perindopril arginine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
Study: NCT05764317
Drug: Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg
Normalized name: amlodipine / perindopril arginine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
Study: NCT05764317
Drug: Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg
Normalized name: amlodipine / perindopril arginine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
Study: NCT04465760
Drug: Xisomab 3G3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV or via catheter
Study: NCT06132919
Drug: MC2-25 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT06132919
Drug: MC2-25 vehicle
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT06018181
Drug: Shuxuetong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to clinical real treatment records
Study: NCT01408069
Drug: MIGRANE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
Study: NCT01408069
Drug: PARCEL
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
Study: NCT05708625
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg daily for 6 weeks or till complete cure
Study: NCT04905147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug 15 mg
Study: NCT06201065
Drug: oxaliplatin , fluorouracil, and leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-HAIC
Study: NCT01351038
Drug: Epirubicine, Oxaliplatin, Capecitabine, Panitumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
Study: NCT04674670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
Study: NCT05102903
Drug: BR1016B
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Study: NCT06359899
Drug: AK0901 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: AK0901, Pharmaceutical Form: Capsule, Route of Administration: Oral
Study: NCT06359899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
Study: NCT04834206
Drug: Docetaxel, nedaplatin, fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
Study: NCT06585540
Drug: Placebo Preventative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will receive placebo (Normal Saline) while under general anesthesia
Study: NCT06585540
Drug: Placebo Treatment
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this Arm will receive placebo as first line treatment of Post-Operative Nausea and Vomiting in the Post Anesthesia Care Unit
Study: NCT05105256
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will have 1 infiltration of 3mL to 5 mL corticosteroids on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with corticosteroids will be performed at inclusion
Study: NCT04958187
Drug: ANG-3777
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm assigned to this intervention will receive 2 mg/kg, IV
Study: NCT06128148
Drug: JYP0322 50 mg qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: JYP0322 is administered orally at a dose of 50 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
Study: NCT06128148
Drug: JYP0322 100 mg qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: JYP0322 is administered orally at a dose of 100 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
Study: NCT06128148
Drug: JYP0322 200 mg qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: JYP0322 is administered orally at a dose of 200 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
Study: NCT06128148
Drug: JYP0322 100 mg bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: JYP0322 is administered orally at a dose of 100 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
Study: NCT06128148
Drug: JYP0322 150 mg bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: JYP0322 is administered orally at a dose of 150 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
Study: NCT06128148
Drug: JYP0322 200 mg bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: JYP0322 is administered orally at a dose of 200 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
Study: NCT01047072
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT04745351
Drug: RDV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as IV saline once daily
Study: NCT04745351
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Treatment for COVID-19 Infection
Study: NCT04771611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Looks exactly like the study drug, but it contains no active ingredient . Oral for four days (days 0,1 and days 8,9)
Study: NCT05037162
Drug: Treatment administration (twice a day)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)
Study: NCT06393634
Drug: Testosterone injection
Normalized name: testosterone Injection
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single injection of testosterone
Study: NCT06393634
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A daily dose of testosterone gel
Study: NCT06393634
Drug: Testosterone Oral
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: A twice-daily pill of testosterone pill to swallow
Study: NCT06224595
Drug: CS32582 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive CS32582 orally single or multiple doses
Study: NCT06224595
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive placebo matching CS32582 orally single or multiple doses
Study: NCT05360966
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular administration of one drop in both eyes BID for 90 days.
Study: NCT05127369
Drug: fluoxetine hydrochloride capsule
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluoxetine hydrochloride capsule
Study: NCT06531161
Drug: Suxiao Jiuxin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxiao Jiuxin Pill is a traditional Chinese medicine compound composed of Ligusticum Wallichii and Borneo Camphorwood, and its clinical safety has been confirmed. Traditional Chinese medicine theory believes that Suxiao Jiuxin Pill has the effects of promoting qi and blood circulation, removing blood stasis and relieving pain, which may help alleviate symptoms of AMS.
Study: NCT05192512
Drug: TQB2928 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2928 injection is a CD47 Blocker.
Study: NCT05997524
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 was given orally twice daily on days 1-14 followed by a 7-day rest interval.
Study: NCT05049278
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Continuous drug: norepinephrine 4mg \* 1@ + D5W 200 mL (20 μg/mL)~* Range: 0.03 \~ 0.09 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)
Study: NCT05737563
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1600 mg/m2/d, oral, 2 weeks on and 1 week off.
Study: NCT05378737
Drug: BAT8006 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
Study: NCT04920383
Drug: ALPN-202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various doses
Study: NCT04744662
Drug: ONL1204 Ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation administered by intravitreal (IVT) injection
Study: NCT05813561
Drug: DWP14012
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 40mg
Study: NCT04630353
Drug: HB-201 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB-201 given IV, one (1) time, on day 1.
Study: NCT04630353
Drug: HB-201 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.
Study: NCT05950906
Drug: PDM608
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDM608 subcutaneous at single or multiple dose(s) assigned by cohort
Study: NCT05950906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous at single or multiple dose(s) to match PDM608 administration.
Study: NCT04704050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.
Study: NCT06270511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an oral suspension.
Study: NCT05205941
Drug: MMV688533
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not exceeding 200mg
Study: NCT05033041
Drug: Study drug placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of placebo (sterile normal saline)
Study: NCT05847764
Drug: RC48+Furmonertinib, 1L
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC48+Furmonertinib in treatment-naive patients harboring EGFR mutations as well as HER2 alterations
Study: NCT05847764
Drug: RC48+Furmonertinib, 2L+
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC48+Furmonertinib in patients who failed at least one line of standard treatment and harboring HER2 alterations
Study: NCT05384262
Drug: AZD0780
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive AZD0780 orally as a single ascending dose.
Study: NCT03252626
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ml normal saline injection added into 10ml 0.9% saline.
Study: NCT05168644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
Study: NCT05384262
Drug: AZD0780
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive AZD0780 orally as a multiple ascending dose.
Study: NCT05384262
Drug: AZD0780
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive AZD0780 orally as a single and multiple ascending dose.
Study: NCT05384262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.
Study: NCT05384262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.
Study: NCT05384262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.
Study: NCT05384262
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive rosuvastatin orally.
Study: NCT06018428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of placebo
Study: NCT04745728
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-2mg/kg/d p.o. with a target accumulated dose of 12g.
Study: NCT05429840
Drug: MT1980
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT05429840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT05124899
Drug: CAP UnScented
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen lip balm.
Study: NCT05124899
Drug: CAP Mountain Berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen lip balm.
Study: NCT04683575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral medication
Study: NCT05283486
Drug: MYMD-1 600MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: 600mg drug
Study: NCT05283486
Drug: MYMD-1 750mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2: 750mg drug
Study: NCT05283486
Drug: MYMD-1 900mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 3: 900mg drug
Study: NCT05283486
Drug: MYMD-1 1050mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 4: 1050mg drug
Study: NCT05283486
Drug: placebo 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: 600mg placebo
Study: NCT05283486
Drug: placebo 750mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2: 750mg placebo
Study: NCT05283486
Drug: placebo 900mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 3: 900mg placebo
Study: NCT06188260
Drug: Systane COMPLETE Lubricant Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Ingredients: Propylene Glycol 0.6% Purpose: Lubricant
Study: NCT05577962
Drug: T group
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation, an experienced anesthesiologist guided by ultrasound performed bilateral superficial cervical plexus block with 0.5% ropivacaine and injected 3-4ml at two points respectively; During the operation, sevoflurane (MAC1.0 - 1.4) was used to maintain the depth of anesthesia
Study: NCT05194007
Drug: Frondanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frondanol capsule (1000 mg) will be administered orally (Twice daily) in the double blind settings
Study: NCT05194007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corn starch) capsule will be administered orally (Twice daily) in the double blind settings
Study: NCT00533741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline for injection.
Study: NCT05975996
Drug: Cyclophosphamide added to standard immunosuppressive therapy with herombopag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. The moderate-dose cyclophosphamide (20mg/kg) will be administered on days 29-30 and days 43-44.
Study: NCT04186299
Drug: Articaine Hydrochloride + Epinephrine
Normalized name: articaine hydrochloride / epinephrine Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive a buccal infiltration of 1.7mL of 4% articaine with 1:100,000 epinephrine.
Study: NCT00093171
Drug: rFIX
Normalized name: rFIXFc
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06173284
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection